AQR Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

AQR Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-9,665	Closed	-$93K	–	2350
2022 Q2	$93K	Buy	9,665 +7,801	+419%	+$73K	﹤0.01%	2099
2022 Q1	$22K	Buy	+1,864	New	+$33.3K	﹤0.01%	2202
2021 Q2	–	Sell	-1,967	Closed	-$147K	–	2311
2021 Q1	$147K	Sell	1,967 -723	-27%	-$75.1K	﹤0.01%	2138
2020 Q4	$292K	Sell	2,690 -1,943	-42%	-$177K	﹤0.01%	1982
2020 Q3	$410K	Buy	4,633 +720	+18%	+$81.8K	﹤0.01%	1809
2020 Q2	$417K	Buy	3,913 +2,450	+167%	+$220K	﹤0.01%	1804
2020 Q1	$87K	Buy	+1,463	New	+$99.3K	﹤0.01%	1980

Other funds holding SYRS

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

AQR Capital Management's SYRS Position: Q3 2022 in Review

AQR Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q3 2022, closing a stake of 9,665 shares — an estimated $93K sold.

AQR Capital Management first reported a position in SYRS in Q1 2020 and held it in 7 quarters. The position peaked at $417K in Q2 2020. 53 funds tracked by Wall St. Rank hold SYRS as of Q3 2022.

AQR Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
AQR Capital Management sold 9,665 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $93K.
AQR Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 7 quarters.
AQR Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $417K in Q2 2020.
53 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on AQR Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.